Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | August 07, 2018 | August 08, 2018 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director · Executive Vice Chairman | March 18, 2026 | March 20, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | July 05, 2023 | July 07, 2023 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | Director · 10% owner | September 12, 2016 | September 22, 2016 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director · CEO | January 08, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date August 07, 2018 · Filed August 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,663 |
Reported balance
After 2018-08-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-07 · Gift · Acquired 14,663 · Balance 24,663 F1: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2: Includes 24,663 shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 14,663 shares of restricted common stock will vest on August 7, 2021.
F2: Includes 24,663 shares of restricted stock.
Fortress Biotech, Inc.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 2,276,562 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 475,424 · Balance 2,276,562 F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.
MUSTANG BIO, INC.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 49,637 |
Reported balance
After 2023-07-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 7,246 · Balance 49,637 F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Includes restricted share units, which vest over various time periods. F4: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date.
F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Includes restricted share units, which vest over various time periods.
F4: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 22, 2016
Jointly reported with FBIO Acquisition, Inc., Fortress Biotech, Inc., Opus Point Partners, LLC, Opus Point Healthcare Innovations (Offshore) Fund Ltd., ROSENWALD LINDSAY A MD
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,037,482 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,037,482 F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 371,584 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 371,584 F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,530 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 89,530 F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,884 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,884 F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,294 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,294 F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
TG THERAPEUTICS, INC.
Report date January 08, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,778,086 |
Reported balance
After 2026-01-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 622,000 · Balance 9,778,086 F1: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period. F2: Includes shares of restricted Common Stock, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.
F2: Includes shares of restricted Common Stock, which vest over various time periods.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | IndirectSee Note 2 | 137,007 |
Reported balance
After 2025-05-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 12,195 · Balance 137,007 F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. |
| COMMON STOCKSEC Table I · non-derivative | IndirectSee Note 2 | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 187,007 · Balance 0 F3: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 187,007 |
Reported balance
After 2025-05-29 transaction · row 2
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 50,000 · Balance 187,007 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board.
F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member.
F3: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2019 Filed Jun 14, 2019 20:43 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 1,179,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-007359 · section16.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 12,828,185 F1 · shares: Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant, but in no event before January 1, 2021. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:50 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 11,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031023 · tv523634_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 37,890 F1 · shares: The 11,442 shares of restricted Common Stock will vest on June 13, 2022, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 16:11 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 648,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019502 · tv516222_4.xml · nonDerivative · entry 3 WEISS MICHAEL S · CIK 0001038977 · Director · EXECUTIVE VICE CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,400,275 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:40 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 14,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042952 · tv500465_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,663 F1 · shares: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2 · balance_after: Includes 24,663 shares of restricted stock. Read SEC document |
| July 03, 2018 Filed Apr 12, 2019 16:11 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 164,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019502 · tv516222_4.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · EXECUTIVE VICE CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,752,071 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 1,018,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007119 · section16.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 11,648,805 F1 · shares: Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 17:21 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 16,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-034452 · tv496605_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 26,448 F1 · shares: The 16,448 shares of restricted Common Stock will vest on June 14, 2021, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Represents shares of restricted Common Stock which vest over various time periods. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 14, 2018 Filed Jan 17, 2020 17:43 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005209 · tm203350d2_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| January 01, 2018 Filed Apr 12, 2019 16:11 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 586,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019502 · tv516222_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · EXECUTIVE VICE CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,587,598 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. Read SEC document |
| June 19, 2017 Filed Jun 19, 2017 22:16 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK (RESTRICTED) | 834,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005710 · section16.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 4 Disclosed balance after: 10,630,794 F2 · shares: Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant; provided however, if the market capitalization threshold is met prior to June 30, 2018 then the shares shall vest on June 30, 2018. F3 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. F4 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 19, 2017 Filed Jun 19, 2017 22:16 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005710 · section16.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,795,917 F1 · security: Reflects the transfer of 350,000 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 17:16 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-032761 · v469071_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 10,000 F1 · shares: The 10,000 shares of restricted Common Stock will vest on June 15, 2020. F1 · balance_after: The 10,000 shares of restricted Common Stock will vest on June 15, 2020. F2 · ownership.nature: The shares were issued to and are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock (Restricted) | 418,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000033 · issuerdirect_section16.xml · nonDerivative · entry 3 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,452,167 F5 · shares: 375,000 shares vest on December 1, 2018 and 43,371 shares vest on December 1, 2019. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock (Restricted) | 2,960,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000033 · issuerdirect_section16.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 4 Disclosed balance after: 9,033,796 F3 · shares: Represents shares of restricted stock which vest based on certain market capitalization milestones. F4 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | Disposition to issuerCommon Stock (Restricted) | 3,381,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000033 · issuerdirect_section16.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073,796 F1 · shares: Mr. Weiss forfeited the shares pursuant to an amendment to his employment agreement effective as of January 1, 2017. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,499,560 shares of Common Stock and 410,450 warrants to purchase Common Stock at $2.48, exercisable through February 24, 2017 issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. Read SEC document |
| January 01, 2017 Filed Jan 27, 2017 16:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 552,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000117 · doc4_4440.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · Exec. VC - Strategic Dev. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,001,170 F1 · shares: Represents an award of restricted shares of the Issuer's common stock made pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock (Restricted) | 693,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000033 · issuerdirect_section16.xml · nonDerivative · entry 4 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 4 Disclosed balance after: 10,145,917 F6 · shares: Reflects an annual grant of restricted stock pursuant to Mr. Weiss? employment agreement to be held by Caribe BioAdvisors, LLC. The restricted shares will vest according to the following schedule: 25% on January 1, 2018; 25% on January 1, 2019; and 50% on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on December 31, 2016. F4 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.